Oral ritodrine and preterm premature rupture of membranes.
A prospective randomized study was performed to determine whether or not oral ritodrine therapy significantly prolonged the latent period in patients with prematurely ruptured membranes. Compared with a control group of similar patients, those treated had a significantly prolonged mean latent period. In addition, 47.6% of the treatment group versus 14.2% of the control group had a latent period of more than one week.
D001724:Birth Weight; D002986:Clinical Trials as Topic; D036861:Delivery, Obstetric; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000188:drug therapy*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011446:Prospective Studies; D011897:Random Allocation; D012312:Ritodrine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D012312:Ritodrine